semaglutide for obesity bmi 25 patients with #obesity, semaglutide, a glucagon-like peptide-1 receptor agonist, is Redefining Obesity Management: Beyond GLP-1

In those with PISD, improvements were shown in overall sexual satisfaction

Insulins Val you Savings Program: This savings program is not insurance

Clinical Considerations Disease-Associated Maternal and/or Embryo/Fetal Risk Maternal obesity increases the risk for congenital malformations, including neural tube defects, cardiac malformations, oral clefts, and limb reduction defects

Neuroprotective effects of GLP-1R agonism GLP-1R agonists improve cerebral blood flow (CBF): By enhancing neurovascular coupling, these drugs ensure that blood flow is properly regulated in response to brain activity, improving overall brain function, particularly in obesity and metabolic disorders